RecruitingNot Applicable

Echocardiography Guided TAVR (Echo TAVR)

China20 participantsStarted 2025-02-18

Plain-language summary

Conventional transcatheter aortic valve replacement (TAVR) relies on fluoroscopic and contrast agents. However, in high-risk patients, exposure to ionizing radiation and contrast agents is contraindicated and undesirable. Echocardiography guidance TAVR can offer a feasible and safer strategy for TAVR.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, which is defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m/s, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2/m2);
✓. a history of malignancy or a high familial risk of cancer, with refusal to undergo contrast- or radiation-guided procedures;
✓. chronic kidney disease and refuse to receive contrast agents or radiation exposure.

What they're measuring

Valve Academic Research Consortium-3 (VARC-3)

Timeframe: 30-day after surgery

Trial details

NCT IDNCT07030062

SponsorPan Xiangbin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Xiangbin Pan, MD

88396655 panxiangbin@fuwaihospital.org

View on ClinicalTrials.gov More Transcatheter Aortic Valve Replacemen trials